Clinical Research Directory
Browse clinical research sites, groups, and studies.
Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE)
Sponsor: George Washington University
Summary
ZAP-DENGUE is a pilot randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of five days of intravenous zanamivir treatment to treat vascular permeability syndrome which is the main cause of death in dengue fever.
Official title: Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE): A Pilot Randomized Controlled Trial
Key Details
Gender
All
Age Range
7 Years - Any
Study Type
INTERVENTIONAL
Enrollment
74
Start Date
2024-03-15
Completion Date
2026-09-30
Last Updated
2025-07-28
Healthy Volunteers
No
Conditions
Interventions
Zanamivir
Intravenous zanamivir
Placebo
In the placebo group, participants will receive placebo normal saline solution intravenously every twelve hours for 5 days.
Locations (2)
Cien Salud IPS SAS
Barranquilla, Atlántico, Colombia
Clinica de la Costa SAS
Barranquilla, Colombia, Colombia